| Fermin Miguel Fontan, MD | |
|
2100 S Triviz Dr Ste G, Las Cruces, NM 88001-0601 | |
| (443) 857-1115 | |
| Not Available |
| Full Name | Fermin Miguel Fontan |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 12 Years |
| Location | 2100 S Triviz Dr Ste G, Las Cruces, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902148885 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD2020-0043 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Medical Center | Las cruces, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Las Cruces Physician Practices, Llc | 7618974858 | 75 |
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.
Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.
The Oral Cancer Foundation recently initiated a program of donating VELscope® Oral Cancer Screening Systems to free clinics and others located in, and helping communities with, underserved populations.
› Verified 8 days ago
| Entity Name | Las Cruces Physician Practices, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093947491 PECOS PAC ID: 7618974858 Enrollment ID: O20061031000215 |
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.
Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.
The Oral Cancer Foundation recently initiated a program of donating VELscope® Oral Cancer Screening Systems to free clinics and others located in, and helping communities with, underserved populations.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fermin Miguel Fontan, MD 2100 S Triviz Dr Ste G, Las Cruces, NM 88001-0601 Ph: (443) 857-1115 | Fermin Miguel Fontan, MD 2100 S Triviz Dr Ste G, Las Cruces, NM 88001-0601 Ph: (443) 857-1115 |
News Archive
Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.
The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment.
Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.
The Oral Cancer Foundation recently initiated a program of donating VELscope® Oral Cancer Screening Systems to free clinics and others located in, and helping communities with, underserved populations.
› Verified 8 days ago
Dr. Kermie Lenard Robinson, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2530 S Telshor Blvd, Suite 103, Las Cruces, NM 88011 Phone: 575-556-6440 Fax: 575-556-6445 | |
Stephen Prange Striegel, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 4351 E Lohman Ave, Suite 200, Las Cruces, NM 88011 Phone: 575-522-4940 Fax: 575-522-4932 | |
Sheikh Altaf Latif, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4351 E Lohman Ave Ste 202, Las Cruces, NM 88011 Phone: 575-522-5955 Fax: 575-522-6228 | |
Kamran Kamali, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2701 Missouri Ave, Suite B, Las Cruces, NM 88011 Phone: 505-522-1931 Fax: 505-532-1665 | |
Charles Monroe Lyon, MD FACS Surgery Medicare: Not Enrolled in Medicare Practice Location: 4311 E Lohman Ave, Las Cruces, NM 88011 Phone: 505-556-6855 | |
Mahli Michael, PA-C Surgery Medicare: Accepting Medicare Assignments Practice Location: 1770 Tierra De Mesilla, Las Cruces, NM 88005 Phone: 575-526-9189 Fax: 575-652-4064 | |
Khalid Y. Khan, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 141 N Roadrunner Pkwy, Suite 137, Las Cruces, NM 88011 Phone: 575-522-1974 |